Table 2.
Performance status |
Co-morbidities [96] |
Gleason grading score |
Prostate specific antigen (PSA half-time, PSA nadir, time to PSA nadir, PSA doubling time after PSA nadir) |
Inflammatory markers (C-reactive protein, IL-6) |
Metabolic markers (body mass index, bone turnover markers) |
Circulating tumor cells (CTC) / CTC genomic characteristics |